168. エーラス・ダンロス症候群
［臨床試験数：7，薬物数：16（DrugBank：8），標的遺伝子数：9，標的パスウェイ数：54］
Searched query = "Ehlers-Danlos syndrome", "EDS", "cEDS", "hEDS", "clEDS", "vEDS", "kEDS", "aEDS", "dEDS", "DDEDS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00190411 (ClinicalTrials.gov) | October 2003 | 13/9/2005 | Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type | Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome | EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT;CHROMOSOME 2q31.2 DELETION SYNDROME | Drug: celiprolol;Drug: Control | Assistance Publique - Hôpitaux de Paris | Aventis Pharmaceuticals | Completed | 15 Years | 65 Years | Both | 54 | Phase 4 | France |